A 4-month programme of in-centre nocturnal haemodialysis was associated with improvements in XXXX outcomes.

@entity1 @entity308 @entity1133 @entity4613 @entity7965 @entity148
BACKGROUND: Extended periods of haemodialysis (HD) can improve @entity1 outcomes. @entity7965 ( @entity7965 ) should be explored as a method of offering extended periods of HD to @entity1 unsuitable for or unable to perform home therapy. METHODS: Ten self-selecting, prevalent HD @entity1 started an @entity7965 programme to assess feasibility and @entity1 satisfaction. Quality-of-life (QOL) measures were evaluated at enrolment and after 4 months of @entity7965 using the EQ-5D, the Hospital Anxiety and @entity308 Scale (HADS) and the SF-12 questionnaires. Demographic, biochemical and haematological data and data on dialysis adequacy were collected before starting @entity7965 and after 4 months. RESULTS: Three of the 10 @entity1 failed to complete the 2-week run-in period. Seven @entity1 completed the 4-month programme, with mean dialysis time of 355    43.92 min throughout the period. The EQ-5D visual analogue score improved from 48    16.89 to 72    13.2 (P = 0.003) and the HADS @entity148 score decreased from 9    5.83 to 3.57    3.04 (P = 0.029). The @entity1133 reduction ratio improved from 71.57    2.29% to 80.43    3.101% (P < 0.001), with improvements in @entity4613 control, reducing to within the target range from 1.73    0.6 to 1.2    0.2 (P = 0.08). Ultrafiltration (UF) volumes increased during the study from 2000    510 to 2606    343 mL (P = 0.015); there was a significant reduction in mean UF rate adjusted for body weight from 6.47    1.71 to 4.61    1.59 mL/kg/h (P = 0.032). Sensitivity analyses confirmed the significance of these results. CONCLUSIONS: This single-centre study showed a 4-month programme of extended hours @entity7965 is safe and associated with improvements in QOL measures, decreased UF rates and measures of dialysis adequacy. These data have been used to expand our service and inform the design of future randomized controlled trials to examine medical endpoints.
